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ABSTRACT
Objective To quantify any risk of atrial ﬁbrillation (AF)
associated with ivabradine treatment by meta-analysis of
clinical trial data.
Methods Medline, Embase, Web of Knowledge and
the Cochrane central register of controlled trials were
searched for double-blinded randomised controlled trials
of ivabradine with a minimum follow-up period of
4 weeks. For studies where AF data were unpublished,
safety data were obtained from the European Medicines
Agency (EMeA) website and personal communications.
Studies were appraised for risk of bias using components
recommended by the Cochrane Collaboration. Meta-
analyses were performed of relative risk of AF and
absolute risk difference of AF per year of treatment.
The main outcome measure was incident AF during the
follow-up period.
Results AF data were available from 11 studies: one
from the published report, six from the EMeA and four
from personal communications. Ivabradine treatment was
associated with a relative risk of AF of 1.15 (95% CI
1.07 to 1.24, p=0.0027) among 21 571 patients in the
meta-analysis. From this we estimated that the number
needed to harm for ivabradine would be 208 (95% CI
122 to 667) per year of treatment.
Conclusions AF is a substantially more common side
effect of ivabradine treatment than one patient in
10 000, the risk presently reported in the product
literature. The incidence of AF has not routinely been
reported in clinical trials of ivabradine.
INTRODUCTION
Ivabradine (Procoralan, Servier) is a heart rate low-
ering drug which acts by speciﬁcally inhibiting the
pacemaker If current, which causes spontaneous
depolarisation in the sino-atrial node that regulates
the heart rate.1 Ivabradine was approved for use by
the European Medicines Agency (EMeA) in 2005
for use in the treatment of stable angina pectoris in
patients with normal sinus rhythm who are not
able to tolerate β-blocker therapy. In 2010, the
indication was extended to include treatment in
patients with uncontrolled angina symptoms and a
heart rate in excess of 60 bpm despite β-blocker
therapy, following the results of the BEAUTIFUL
trial.2 A new indication was approved in 2012, fol-
lowing the results of the SHIFT trial, for treatment
of chronic heart failure (New York Heart
Association class II–IV) with systolic dysfunction, in
patients in sinus rhythm and whose heart rate is
greater than 75 bpm, in combination with standard
therapy, including β-blocker therapy, or when
β-blockers are contraindicated or not tolerated.3
Use of ivabradine is yet to be approved by the US
Food and Drug Administration.
Genome-wide association studies have identiﬁed
associations between genetic variants in the region
of the gene HCN4, which codes for the main ion
channel responsible for the If current, and both
heart rate and atrial ﬁbrillation (AF).4 5 The pul-
monary venous myocardium, which is an important
source of AF initiation and maintenance,6 demon-
strates an If current which is affected by ivabra-
dine.7 This raises the possibility that ivabradine
treatment may affect AF risk. AF is common in
patients with coronary artery disease and cardiac
failure8 and so incident AF in the target population
for ivabradine treatment would not necessarily be
attributed to the drug. It has been shown that
genome-wide association study hits can identify
therapeutic targets and provide insight into drug
side effects. For example, a single nucleotide
plymorphism (SNP) in the tumour necrosis factor
receptor 1 gene which is associated with multiple
sclerosis (MS) risk has been shown to explain the
mechanism whereby antitumour necrosis factor
therapies typically exacerbate MS.9 We therefore
examined whether there was a signiﬁcant increase
in AF risk associated with ivabradine treatment by
meta-analysis, and quantiﬁed that risk in terms of
number needed to harm (NNH) per year.
METHODS
The study was performed in line with the recom-
mendations of the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
statement.10
Eligibility criteria, information sources
and search protocol
We included in our analysis all randomised con-
trolled double-blind trials of ivabradine, for any
indication and of any size, which followed patients
up for at least 4 weeks. We did not exclude studies
where AF incidence was not reported in the pub-
lished manuscript, but attempted to identify that
data wherever possible. We included both placebo-
controlled studies and non-inferiority studies where
an alternative drug treatment was used as a com-
parator. We excluded open or single-blinded
studies, studies where the follow-up period was less
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than 4 weeks and studies where there was signiﬁcant risk of
bias, as assessed by the methods recommended by the Cochrane
Collaboration.
We performed a systematic search, without language restric-
tion, for randomised clinical trials of ivabradine treatment for
any indication, using the search term ‘ivabradine’ and the docu-
ment type ‘clinical trial’ or ‘randomized controlled trial’. We
searched Medline, Embase and Web of Knowledge from 1980
to October 2013, and the Cochrane Central Register of
Controlled Trials. We also examined the reference lists of pub-
lished trials, review articles and meta-analyses to identify other
eligible trials. We read the scientiﬁc discussions of the EMeA to
identify safety data that were not published in the original trial
report. We also contacted directly the authors and in the case of
industry-sponsored trials, the sponsors of studies which did not
report the AF incidence in the original manuscript.
Selection and quality assessment
Studies were assessed on the basis of their title or abstract and
those studies which appeared to meet the eligibility criteria were
selected for full text review. Trials were assessed for eligibility
and risk of bias using the components recommended by the
Cochrane Collaboration: sequence generation, allocation con-
cealment, blinding of participants, personnel and outcome asses-
sors, incomplete outcome data, selective outcome reporting and
other sources of bias.11 We considered any trial with a high or
unclear risk of bias, by the Cochrane criteria, in sequence gener-
ation, allocation concealment and blinding to be at high risk of
bias; all other studies were considered to be at low risk of bias.
Outcome measures and data collected
The main outcome measure was incident AF reported during
the trial follow-up period. Where data on AF incidence were
not reported, we contacted the authors by email on at least two
occasions. We also identiﬁed AF incidence reported in the
EMeA scientiﬁc discussions where trials were submitted as evi-
dence for licensing and, in the case of trials sponsored by the
manufacturer, contacted the manufacturer directly. Study data
were collected on data collection forms which recorded
reference data, ethical approval, randomisation, blinding,
control agent (placebo or other drug), follow-up duration,
inclusion and exclusion criteria and sponsorship and funding
information as well as numbers of patients in the ivabradine and
control arms with incident AF.
Statistical analyses
We performed meta-analysis of intention to treat outcomes
using a random effect model in the metafor package in R statis-
tical software V.3.0.2.12 13 Detailed statistical methods are avail-
able in the online supplement.
RESULTS
Study selection and characteristics of included trials
Our initial search strategy identiﬁed 84 published articles. We
reviewed titles and abstracts and excluded papers that were not
clinical trials, were not of sufﬁcient duration of follow-up or
which reported supplementary data from trials published else-
where. We assessed the full text of the remaining 34 articles
for eligibility. Eight papers were translated into English. After
studies were excluded on the basis of study design (one),
follow-up duration (two), randomisation (nine), study blind-
ing (10) and duplication (two), our search strategy yielded 10
double-blind randomised controlled trials that enrolled
20 022 patients for a mean of 1.5 (range 0.076–1.88) years
follow-up, for a total of 30 090 patient-years of follow-up
(table 1, ﬁgure 1).2 3 14–22 Risk of bias of the included studies is
summarised in online supplementary table S1. Of the 10 studies
identiﬁed, AF incidence was only reported in one, the SHIFT
trial. We wrote to the authors of the other studies to request the
unpublished AF data. Of the ﬁve studies not sponsored by the
manufacturer, four authors replied with AF data. None of the
authors of studies sponsored by the manufacturer provided AF
data. We contacted the manufacturer directly who declined to
provide the unpublished data, citing ongoing inhouse analyses. Of
the missing studies, full AF safety data were provided for the
BEAUTIFUL study on the EMeAwebsite. The safety data from the
ASSOCIATE study which is reported in the EMeA documentation
do not report the incidence of AF. The data from the INITIATIVE
Table 1 Eligible trials for which AF data were sought
Author Year Acronym
Number of
participants Indication Control
Ivabradine
dose (bid) AF data source
Tardif et al14 2005 INITIATIVE 939 Angina Atenolol 7.5 mg/10 mg Included in OOSS
Ruzyllo et al15 2007 1195 Angina Amlodipine 7.5 mg/10 mg Included in OOSS
Fox et al2 2008 BEAUTIFUL 10 907 Heart Failure Placebo 5 mg/7.5 mg EMeA
Tardif et al16 2009 ASSOCIATE 889 Angina Placebo 5 mg/7.5 mg No data
Fasullo et al17 2009 155 Anterior STEMI Metoprolol 5 mg/7.5 mg No data
Swedberg et al3 2010 SHIFT 6492 Heart Failure Placebo 2.5–7.5 mg Original paper
Nerla et al18 2012 61 Type II diabetes Atenolol/placebo 5 mg Personal communication
Dominguez-
Rodriguez et al19
2012 27 NSTE-ACS Placebo 5 mg Personal communication
Cappato et al21 2012 21 IST Placebo 5 mg Personal communication
Villano et al22 2013 46 Microvascular angina Ranolazine/placebo 5 mg Personal communication
EMeA 2005 OOSS 3936 Atenolol/amlodipine/placebo 5–10 mg EMeA
The AF data for the INITIATIVE study and from Ruzyllo et al were not available separately, but were included in the OOSS from the EMeA with three other studies.
AF, atrial fibrillation; bid, twice daily; EMeA, European Medicines Agency; IST, inappropriate sinus tachycardia; NSTE-ACS, non-ST elevation acute coronary syndrome; OOSS, overall oral
safety set; STEMI, ST elevation myocardial infarction.
Trial acronyms: ASSOCIATE: Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-
controlled trial. BEAUTIFUL:Ivabradine for patients with stable coronary artery disease and left ventricular dysfunction (BEAUTIFUL): a randomized, doube-blind, placebo-controlled trial.
INITIATIVE: Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. SHIFT: Systolic Heart Failure Treatments with If Inhibitor
Ivabradine Trial.
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study and from Ruzyllo et al are included in the analyses per-
formed by the EMeA for licensing of ivabradine. The data are not
available for each trial individually, however, but are combined
with the safety data from a 3-month phase III clinical trial (for
which we were unable to identify a published report) and two
very short (four doses and 2 weeks, respectively) dose-ranging
phase II studies. All of the studies included in this overall oral
safety set (OOSS) were randomised, controlled and double-
blinded. None of the trials for which we obtained AF incidence
data separately were included in the OOSS. In order to provide
the most accurate estimate of the effect of AF, we decided to
include the OOSS as a single study in our meta-analysis and also
to perform two sensitivity analyses. In the ﬁrst, the OOSS was
excluded and in the second only those trials where the drug treat-
ment was compared with placebo, rather than an alternative such
as amlodipine or a β-blocker, were included.
In our full data set for analysis including the OOSS, therefore,
there were 21 571 patients, followed up for a mean of
1.43 years to provide a total of 30 755 patient-years of
follow-up. When the OOSS was excluded, the data set included
17 635 patients, followed up for a mean of 1.67 years to give a
total of 29 385 patient-years of follow-up. In the placebo-
controlled trials only data set, there were 17 571 patients fol-
lowed up for a mean of 1.67 years to give a total of 29 380
patient-years of follow-up.
AF incidence
Compared with controls, treatment with ivabradine was asso-
ciated with a relative risk (RR) of AF of 1.15 times that of
alternative treatments (95% CI 1.07 to 1.24, p=0.0027) (ﬁgure
2). The results were largely similar if the OOSS was excluded,
RR=1.15 (95% CI 1.06 to 1.25, p=0.0065) and if only
placebo-controlled trials were examined, RR=1.15 (95% CI
1.05 to 1.26, p=0.015). When treatment indication was
included in the model, the association between treatment indica-
tion and AF risk was not signiﬁcant (p=0.99), although this
analysis was limited as the majority of patient-years of follow-up
(17 475/17 635) were in the two trials (SHIFT and
BEAUTIFUL) for which the main treatment indication was heart
failure.
When the absolute risk of AF was compared between ivabra-
dine and control groups, ivabradine treatment was associated
with an NNH of 208.3 per year of treatment (95% CI 122.0 to
666.7, p=0.013) (ﬁgure 3). This corresponds to an absolute
risk difference of 0.48%. This effect was very similar when the
OOSS was excluded, NNH=208.3 (95% CI 113.6 to 1250,
p=0.028) and when only placebo-controlled trials were
included, NNH=208.3 (95% CI 105.3 to 10 000, p=0.048).
As ivabradine is indicated for chronic treatment of angina or
cardiac failure and treatment is likely to continue for more than
1 year, this NNH represents a substantially greater risk than the
very rare (less than 1 : 10 000) risk of AF reported in the
product literature.
The heterogeneity of RR in the trials included was low,
I2=0.00%, with the observed heterogeneity explained by
within-study variance (p=0.96). The same was true in the ana-
lysis of absolute risk difference, I2=0.00%, where the residual
heterogeneity after accounting for length of follow-up was
Figure 1 Flow chart of study selection.
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explained by within-study variance (p=0.86). This explains the
similarity of the meta-analysis results between subgroups of
trials.
There was no evidence of publication bias, rank test p=1.00
and regression test p=0.64, and examination of the funnel plots
did not suggest any missing data (ﬁgure 4).
DISCUSSION
The results of this study, which used as much of the safety data
as were available, quantify the risk of AF associated with ivabra-
dine treatment. Use of ivabradine is associated with an approxi-
mately 15% increase in the risk of developing AF. This risk is
greater than previously reported in the product safety
information.
AF is a common complication of coronary artery disease and
cardiac failure. Patients with these conditions have a higher rate
of complications from AF than patients with AF alone.23 In add-
ition, ivabradine has not been shown to limit the ventricular
rate in patients in AF, and so those patients who develop AF are
likely to have higher heart rates, thus negating any beneﬁts of
ivabradine as a rate-lowering therapy in treating either angina or
cardiac failure. These risks however need to be balanced against
the beneﬁts of ivabradine. In the SHIFT study, ivabradine
treatment resulted in a reduction in the composite endpoint of
death or hospitalisation with worsening heart failure; the
number needed to treat (NNT) was 26, which was largely
driven by a reduction in hospitalisations.3 A combined analysis
of the individual data from the SHIFT trial and those patients
in the BEAUTIFUL trial with a baseline heart rate ≥70 bpm also
identiﬁed a reduction in the same endpoint; the NNT was
40.7.24 Interestingly, in the same analysis, which looked at
patients with a higher baseline heart rate, the increase in AF
incidence was greater than we found in our meta-analysis; the
NNH was 58 (albeit over a longer follow-up of 19–22 months).
This raises the possibility that it is the patient group with the
most to gain from ivabradine treatment who have the greatest
risk of developing AF and that the absolute increase in the risk
of AF with ivabradine treatment in this group is of a similar size
to the absolute decrease in risk of hospitalisation.
The associations between genetic markers near HCN4, com-
bined with the results of this meta-analysis, which identiﬁes an
association between If current inhibition and AF, provide further
evidence for the role of HCN4 and the If current in the patho-
physiology of AF. The results of this analysis also highlight the
importance of large safety data sets and ongoing postmarketing
surveillance of licensed and approved medications to identify side
Figure 2 Forest plot of relative risk of atrial ﬁbrillation in all trials with available data. RE Model, random effects model.
Figure 3 Number needed to harm per year of follow-up. Individual
studies are plotted as circles with size proportional to the weighting in
the meta-analysis model of absolute risk difference. The best ﬁt line
with 95% CI (dashed lines) is shown.
Figure 4 Funnel plot of relative risk versus SE. The plot is largely
symmetrical, suggesting that there is no publication bias.
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effects which might otherwise be dismissed as complications of the
underlying disease in a patient group with signiﬁcant comorbidity.
Limitations
We were not able to obtain the incidence of AF for all of the
trials which we identiﬁed, and the funnel plot shows a relative
lack of mid-sized trials, which reﬂects this. The use of the OOSS
from the EMeA scientiﬁc discussion may have resulted in an
underestimation of the heterogeneity of the data available. Five
studies, possibly quite different in various ways from each other,
were combined to form a single data set that was treated in the
analysis as a single trial. This is likely to result in an overesti-
mation of within-study variance and an underestimation of
between-study variance. We have attempted to ameliorate this by
performing sensitivity analyses in which the OOSS is excluded.
As the AF data for the largest trials which studied patients
with angina, rather than heart failure, were not available separ-
ately for each trial, we were unable to deﬁnitively assess the effect
of treatment indication on AF risk. It is possible that AF is less
common as a side effect of ivabradine treatment in patients with
angina pectoris rather than heart failure. However, a deﬁnitive
assessment of this risk would require analysis of the individual
trial data from the angina studies and possibly even a prospective
study of angina patients similar in size to the SHIFT and
BEAUTIFUL studies. Such a trial is unlikely to be conducted.
We are unable to provide data comparing the AF risk proﬁle
of patients who developed AF to those who did not in either
the ivabradine treatment or control groups. It is possible that
the increase in AF risk is restricted to a small high-risk subgroup
within the overall study population for each trial.
CONCLUSIONS
Ivabradine treatment is associated with a 15% increase in the
RR of AF. We estimate that 208 patient-years of treatment with
ivabradine would be required to cause one new case of AF.
Key messages
What is known on this subject?
Ivabradine is an effective heart rate lowering treatment which
reduces symptoms in chronic stable angina and reduces
hospitalisations in chronic heart failure.
Ivabradine may carry an increased risk of atrial ﬁbrillation (AF).
What might this study add?
Ivabradine treatment carries a substantially higher risk of AF
than previously thought; we estimate that 208 patient-years of
treatment would be required to cause one new case of AF.
How might this impact on clinical practice?
The risk of AF needs to be taken into consideration when weighing
the balance of risk and beneﬁts of ivabradine treatment.
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